my mother is taking 150mg of menofos once a month
Menofos is Alendronate Sodium; Class: Vitamin & Minerals and is indicated for:
Treatment and prevention of osteoporosis in postmenopausal women
For the treatment of osteoporosis, alendronate sodium increases bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures). Osteoporosis may be confirmed by the finding of low bone mass (for example, at least 2 standard deviations below the premenopausal mean) or by the presence or history of osteoporotic fracture.
For the prevention of osteoporosis, alendronate sodium may be considered in postmenopausal women who are at risk of developing osteoporosis and for whom the desired clinical outcome is to maintain bone mass and to reduce the risk of future fracture.
Bone loss is particularly rapid in postmenopausal women younger than age 60. Risk factors often associated with the development of postmenopausal osteoporosis include early menopause; moderately low bone mass (for example, at least 1 standard deviation below the mean for healthy young adult women); thin body build; Caucasian or Asian race; and family history of osteoporosis. The presence of such risk factors may be important when considering the use of alendronate sodium for prevention of osteoporosis.
Treatment to increase bone mass in men with osteoporosis
Treatment of glucocorticoid-induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density. Patients treated with glucocorticoids should receive adequate amounts of calcium and vitamin D.
Treatment of Paget's disease of bone in men and women
reatment is indicated in patients with Paget's disease of bone having alkaline phosphatase at least two times the upper limit of normal, or those who are symptomatic, or those at risk for future complications from their disease.
The safety and effectiveness of alendronate sodium for the treatment of osteoporosis are based on clinical data of four years duration. The optimal duration of use has not been determined. All patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis.
However, please do also seek advice from a doc/pharmacist. Take care, best wishes.
Search for questions
Still looking for answers? Try searching for what you seek or ask your own question.
Posted 29 Mar 2011 • 1 answer
Posted 29 Apr 2011 • 3 answers
Posted 21 Jun 2011 • 1 answer
Posted 25 Oct 2011 • 1 answer
Posted 27 Jun 2016 • 0 answers